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ABSTRACT
Introduction: There is an increasing interest for
real-life data on drug use in many countries.
Reimbursement authorities more and more
request observational studies to assess the
conditions of use of the products but also to
improve knowledge about efficacy and safety in
the real world and on a longer term than in
clinical trials.
Aim: To evaluate the effectiveness, treatment
persistence and tolerability of vildagliptin in
clinical practice.
Methods: This observational, 2-year
prospective cohort study was conducted in
France on request of the Health Authorities
[Haute Autorite de Sante (HAS)]. Type 2 diabetic
mellitus (T2DM) patients initiating vildagliptin
(including the fixed combination vildagliptin-
metformin) or treated for \6 months were
recruited through a national representative
sample of general practitioners (GPs) (n = 482)
and diabetologists (n = 84) between March 2010
and December 2011. At inclusion and each
follow-up visit at* 6, 12, 18 and 24 months, a
questionnaire was completed by the physician
collecting information on socio-demographic,
clinical and biological data, treatments and
adverse events.
Results: 1,700 patients were included: 60%
were males, aged 63 ± 11 years, with diabetes
duration 7 ± 6 years and body mass index (BMI)
30 ± 6 kg/m2. 45% were obese, 70% treated for
hypertension and 66% for dyslipidemia. 64% of
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the patients received vildagliptin in dual
therapy with metformin. 82% of patients
completed the 2-year follow-up. Glycosylated
hemoglobin (HbA1c) decreased from a mean
baseline of 7.8 ± 1.2% when vildagliptin was
started, to 7.0 ± 1.1% at 6 months and
remained stable thereafter over 2 years. Mean
weight, glomerular filtration rate, liver
enzymes, and lipid parameters were
unchanged over the study period. Eight
patients (0.5%), all concomitantly treated with
insulin and/or sulphonylureas, reported one
severe hypoglycemia and 47 (2.9%) patients
reported 64 non-severe symptomatic
hypoglycemia (59% occurred when patients
were treated with insulin and/or
sulphonylureas). At 6 months, 44.9% of
vildagliptin-treated patients reached an HbA1c
\7% without hypoglycemia and no weight
gain, and this percentage increased to 49.7% at
24 months. Vildagliptin treatment maintenance
at 2 years was 88.8% [95% CI (87.2%; 90.4%)],
with 4% of patients discontinuing for adverse
events.
Conclusions: In everyday conditions of care,
vildagliptin efficacy was in line with existing
data from randomized clinical trials, sustained
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INTRODUCTION
The prevalence of type 2 diabetes mellitus
(T2DM) is dramatically rising across the world,
largely fueled by the epidemic of obesity and
aging of the population [1]. The International
Diabetes Federation (IDF) estimates that 382
million people have diabetes in 2013 and this
will rise to 592 million by 2035 [2]. In the USA,
8.3% of the population has T2DM [3], close to
the overall latest 2013-IDF estimated prevalence
of 8.5% in Europe [4]. In France, diabetes affects
4–5% of the adult population [5]. Prevention
and treatment of the disease and its
complications pose a major burden on
national healthcare systems worldwide,
accounting for 12% globally of the health
expenditures in 2010 [6] and thus constitute
one of the most challenging global health issues
of the twenty-first century.
In addition to lifestyle changes, effective and
safe pharmacological therapies are needed to
manage T2DM. Several new classes of
antidiabetic agents have recently been
introduced in the management of T2DM. The
2012 position statement of the American
Diabetes Association (ADA) and the European
Association for the Study of Diabetes (EASD)
reviews advantages and disadvantages of all
available classes and proposes a patient-
centered approach, taking into account patient
preferences, effects on body weight and on
hypoglycemia risk, cost and potential side
effects of each class [7]. The latest 2013 HAS-
French guidelines, however, recommend a more
prescriptive algorithm with sequential choices
essentially guided by long experience with the
drugs and economic considerations [8].
Vildagliptin is a member of the new class of
dipeptidyl peptidase 4 (DPP4) inhibitors that
work by maintaining high levels of endogenous
incretins. This leads to improved sensitivity of
a- and b-cells to glucose, which results in
glucose-sensitive modulation of insulin and
glucagon secretion [9]. Vildagliptin has been
shown to improve both fasting and
postprandial glycemic control in T2DM
patients [10] with a low risk of hypoglycemia
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[11], and is effective across a wide disease
spectrum, from newly diagnosed patients [12,
13] to patients with long-standing T2DM [14–
17]. Indeed, the overall magnitude of
glycosylated hemoglobin (HbA1c) reduction
has been found to be more or less similar
throughout treatment stages, when used in
monotherapy [18], in combination with one
[10, 19, 20] or two oral antidiabetic drugs
(OADs) [21] or with insulin [22]. A
hypoglycemia risk similar to placebo has
consistently been seen with vildagliptin [11]
including in high-risk patients such as elderly
patients [23–25], patients with renal impairment
(RI) [27–29] and/or patients treated with insulin
[14, 30].
While the drug has been extensively studied
in multiple randomized clinical trials (RCTs),
additional data from large, non-selected patient
populations in the real-world environment are
valuable complements, which may be more
applicable to daily management of T2DM [31].
In the present observational study, the
authors have set out to evaluate the
effectiveness, treatment persistence and
tolerability of vildagliptin over 2 years




The VILDA study was a prospective,
multicenter, observational study with a 2-year
follow-up of patients with T2DM treated with
vildagliptin (including the fixed combination of
vildagliptin ? metformin) under real-life
conditions in mainland France. It was
requested by French Health Authorities [Haute
Autorite´ de Sante´ (HAS)] which reviewed and
approved the study design and protocol. The
objectives were to describe the characteristics of
patients treated with vildagliptin and the
conditions of use of the product, the
maintenance rate and the frequency of/and
reasons for treatment discontinuation, as well
as to confirm the efficacy/safety profile
(specifically the changes over time in HbA1c
and weight and the incidence of hypoglycemia
over 2 years) under routine clinical care. In
2009, the indications listed in the vildagliptin
Summary of Product Characteristics (SPC)
were the use in dual therapy (as add-on to
metformin, sulfonylureas or a thiazolidinedione
if glycemic control was not obtained under
monotherapy), while in 2012 additional
indications for use as monotherapy, triple
therapy or in combination with insulin had
been added to the SPC.
The study was conducted by general
practitioners (GPs) and specialists in
endocrinology, diabetology and metabolic
diseases (SPE) treating diabetic patients. 41,000
GPs were randomly drawn from a national
database of all GPs practicing in France in
2009 and invited to participate by mail; 1,125
(2.7%) agreed to participate and 483 included at
least one patient. From all 1,878 diabetologists
practicing in France in 2009, 187 (10%) agreed
to participate and 84 included at least one
patient. Each participating physician had to
include consecutively 1–5 patients. The
physicians were free to treat and follow-up
their patients as they saw fit, with no
alteration in the physician–patient
relationship, T2DM management and
monitoring. During the period of inclusion,
investigators had to complete a registry of non-
inclusion with the characteristics of patients
who attended a consultation during the
inclusion period and were eligible but were
not included in the VILDA study, and the
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reasons for non-inclusion. Patients were
recruited between March 2010 and December
2011.
Patients
All adult patients with T2DM spontaneously
visiting a study physician (independently of the
study), who had already started vildagliptin
within the past 6 months or were about to
start treatment with vildagliptin on the visit
day, and who had agreed to participate in this
study, were eligible for inclusion. Patients
included in an interventional clinical trial or
who had participated in one in the last
3 months, and those presenting a substantial
risk of not being followed-up for 2 years
(moving house, emigration, etc.) were not
included in the study.
Assessments
At inclusion and each follow-up routine visit at
approximately 6, 12, 18 and 24 months, a
questionnaire was completed by the physician
collecting information on socio-demographic,
clinical (disease history, comorbidities, diabetes
complications, concomitant therapies and
lifestyle measures) and available biological
data (no test was required by the protocol in
this observational study), anti-diabetic
treatments and adverse events (AEs). Micro
and macro-vascular complications data were
those declared by the investigators (no
definition was provided in the protocol or
cross-checking with collected biological data).
Patient satisfaction with anti-diabetic treatment
was measured using the Diabetes Treatment
Satisfaction Questionnaire status version
(DTSQs prior to vildagliptin initiation) and the
Diabetes Treatment Satisfaction Questionnaire
change version (DTSQc) [32] subsequently, to
measure satisfaction in relation to the change in
therapeutic strategy. The overall DTSQs score is
interpreted such that the higher the score, the
greater the satisfaction (with a maximum at 36).
The total DTSQc score ranges from -18 to ?18.
Outcome measures were those requested by
HAS, namely the conditions of use of the
product (proportion of patients who comply
with the indications and precautions for use
listed in the SPC); treatment maintenance rate
over 2 years with frequency of/and reasons for
treatment discontinuation; changes from
baseline up to 2 years in HbA1c levels (with
both measurements performed at the same local
laboratory using a Diabetes Control and
Complications Trial reference method), and
in body weight; the rate of hypoglycemia
over 2 years, including all symptomatic
hypoglycemia (with adrenergic and/or
neuroglycopenic symptoms corrected after
glucose administration) and severe
hypoglycemia (requiring assistance of another
person, coma, hospitalization). The proportion
of patients for whom ‘‘therapeutic success’’ was
met (defined as reaching an HbA1c\7% without
a single episode of hypoglycemia and without
weight gain greater than 5% of baseline) was
analyzed at 6, 12 and 24 months of treatment.
Available biological data were collected at each
visit (in addition to fasting plasma glucose and
HbA1c levels). They included creatinine levels
and estimated glomerular filtration rate (eGFR)
calculated using the Modification of Diet
in Renal Disease (MDRD) formula [33],
transaminase levels and all lipid parameters.
All AEs and serious AEs (SAEs) together with
their severity and relationship to the study
treatment were documented at each visit and
analyzed in the whole population recruited in
the study.
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Statistical Analyses
Quantitative or continuous variables were
described by mean and standard deviation
(SD) and in some cases median and range.
Qualitative variables were described by absolute
frequency and percentage per modality.
Quantitative variables were compared between
groups by Student tests in case of normal
distribution and Wilcoxon-Mann–Whitney test
otherwise. Qualitative variables were compared
between groups using the Pearson Chi-square
test if all theoretical sample sizes were C5 or
using the Fisher test if \5. All tests were
performed with a significance level of 5%. All
statistical analyses were performed using SAS
9.2 software (SAS Institute, Cary, NC, USA).
To verify the representativeness of the
physicians participating in the study, their
characteristics were compared to those of all
French physicians (age, gender, type and place
of work). This analysis was performed separately
for the GPs and for the endocrinologists.
Representativeness of the patients included in
the study was checked by a comparison with
patients of the non-inclusion registry, a
comparison of patients whose treatment began
in the \6 months prior to the inclusion date
with patients included on the day of
vildagliptin initiation, and a comparison of
patients who did not complete the study with
those followed-up throughout the entire study
period over the four planned visits.
Patient data were analyzed separately
according to physician specialty (general or
specialist practitioners) and pooled without
weighting the sample.
Sample size was set to guarantee sufficient
accuracy of the proportion of patients meeting
the conditions of use of vildagliptin (estimated
at 50%). A cohort of 1,000 patients allowed to
estimate this proportion with a precision of
about 3% at a confidence level of 95%; to take into
account an expected *20% drop-out rate over
2 years, the sample size was thus set at 1,300
patients needed to be included in the study.
Compliance with Ethics
All procedures followed were in accordance
with the ethical standards of the French Order
of Physicians and Good Practices for
Epidemiological Studies and with the Helsinki
Declaration of 1975, as revised in 2000 and 2008.
Candidates for inclusion were provided with full
written information about the study. All data
processing was carried out in compliance with
French Information Technology and Privacy Law.
RESULTS
Patient’s Flow Chart and Baseline
Characteristics
A total of 1,763 patients were enrolled in the
study, 1,700 were kept in the initial analysis and
1,639 in the follow-up analysis (see Fig. 1 for
patients’ flow chart). The mean follow-up
period was 22.9 months, with 80.6% of
patients followed for C22 months.
Of the 1,700 patients, 26% were treated
with vildagliptin and 74% with the fixed
vildagliptin-metformin combination. 37.8% of
patients had started vildagliptin within the
previous 6 months and 62.2% started vildagliptin
on the day of inclusion.
Of the 567 investigators (483 GP and 84 SPE)
who included at least one patient, 392 (337 GP
and 55 SPE) returned the registry of non-
inclusion (n = 1,457 patients). The comparison
between these 1,457 patients with those
included in the study did not identify any
potential selection bias, though patients
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included in the study were slightly younger
(62.5 years). The reasons for not including
patients were: patient’s refusal to participate
(41%), anticipated difficulties for the follow-up
(37%), no time to include the patient at the
time of the visit (17%) and other reasons (5%).
Fig. 1 Patients’ disposition
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Physicians
No major bias was found in terms of
representativeness of the physicians in the
different analyses: participating GPs were
comparable to all GPs in France with respect
to age, area and place of practice, whereas
females were under-represented. Patients
included by male and female GP were thus
compared, and this analysis did not identify any
significant difference between these two
populations.
Characteristics of the VILDA Population
Patients’ demographic characteristics together
with details of their diabetes are presented in
Table 1, overall and by physicians (GPs or SPE).
Overall, the mean (±SD) age of the population
was 63.1 (±10.9) years, with a male
predominance (60.0%) and a mean body mass
index (BMI) of 30.2 (±5.6) kg/m2, with about
84% of overweight and 45% of obese patients.
Mean disease duration was 7.0 (±6.5) years and
mean HbA1c was 7.8% (±1.2). Most patients had
associated cardiovascular risk factors, 70.1%
were treated for hypertension and 66.4% for
dyslipidemia. According to the investigators,
37.0% of patients complied properly with their
recommendations to engage in regular physical
activity and 51.0% with their dietary advices.
A microvascular complication was reported in
1/3 of the population, mainly nephropathy
(albuminuria in 12.6% of patients and renal
impairment in 2.8%), diabetic retinopathy
(4.5%) and erectile dysfunction (22.8% of men).
A macrovascular complication was described in
14.3% of patients, predominantly coronary artery
disease (12.5%). Patients included by SPE did not
seem to have a more advanced diabetic disease
than those included by GPs. Tolerability issues
with previous antidiabetic treatment were
reported by 15.9% of patients. A history of
symptomatic hypoglycemia was reported by
42.4% of patients previously treated by insulin
secretagogues (sulphonylureas or meglitinides)
and that of severe hypoglycemia by 3.7% of
them. The baseline average DTSQs score (before
vildagliptin initiation) was 21.5 ± 5.9 with GPs
and 23.2 ± 6.0 with SPE.
Conditions of Use
Previous antidiabetic therapy was based on
monotherapy in about half of the cases, dual
therapy in over a third and triple therapy in
about 13%. Only 2% of the patients were drug-
naı¨ve. The main reason for vildagliptin
initiation was the need to improve glycemic
control (in 83.8% of cases for GPs and 71.6% for
SPE); previous hypoglycemia was a reason for
vildagliptin initiation in only 3.0% of the case
for GPs and in 8.3% of the cases for SPE.
At treatment initiation, vildagliptin was used
in monotherapy in 5.4% of the cases, in dual
therapy in 69.4% of the cases (essentially in
combination with metformin in 64%), in triple
oral therapy or more in 22.8%, and in
combination with insulin in 2.5% of the cases.
In total, 69.4% (1,179) of the VILDA
population received vildagliptin appropriately as
dual therapy (in addition to metformin,
sulfonylureas or thiazolidinedione), which were
the approved indications in 2009. However, 6.4%
of these patients were not in compliance with the
SPC, mostly because of sufficient glycemic control
prior to the introduction of vildagliptin (HbA1c
\6.5%). Overall, misuse according to the
2009-SPC was, therefore, found in 37.3% of
patients. However, based on the 2013-SPC,
which incorporates the new indications for
vildagliptin (in monotherapy, triple therapy and
combination with insulin), this percentage drops
to 12.1% of patients.
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Table 1 Baseline demographic and disease characteristics
GP SPE Total
N =1,471 N 5 229 N 5 1,700
Age (years)
Mean ± SD 63.4 ± 10.9 61.1 ± 10.7 63.1 ± 10.9
Age group (years)
C75 14.8% 8.3% 13.9%
Sex
Male (%) 61.0% 54.1% 60.0%
Body mass index (kg/m2)
Mean ± SD 30.2 ± 5.5 30.5 ± 6.2 30.2 ± 5.6
BMI C30 kg/m2 (%) 47.8% 42.5% 45.4%
HbA1c (%)
Mean ± SD 7.8 ± 1.2 7.5 ± 1.2 7.8 ± 1.2
Median 7.6 7.3 7.6
HbA1c (%) groups
B7% 23.8% 38.9% 25.8%
C8% 37.0% 27.4% 35.7%
Fasting plasma glucose (mg/dL)
Mean ± SD 160 ± 50 150 ± 40 160 ± 50
Diabetic complications
Microvascular complication
% of patients 32.7 34.3 32.9
Macrovascular complication
% of patients 14.6 12.9 14.3
Duration of T2DM (years)
Mean ± SD 6.8 ± 6.4 8.3 ± 7.4 7.0 ± 6.5
Median (range) 5.0 (0.0–50) 7.0 (0.0–43) 5.0 (0.0–50)
% with history[5 years 47.4% 57.0% 48.8%
Previous OAD treatment
Naı¨ve (%) 1.8 3.0 2.0
Monotherapy (%) 50.1 40.2 48.8
Dual therapy (%) 35.2 37.6 35.5
Triple therapy and more ± insulin (%) 12.8 19.2 13.7
Mean DTSQs score 21.2 ± 5.9 23.2 ± 6.8 21.5 ± 6.0
Median (range) 21.0 (6.0–36.0) 24.0 (9.0–36.0) 21.0 (6.0–36.0)
History of Hypoglycemia (%) 8.6 14.7 9.4
Main cardiovascular risk factors
Smokers (current or stopped\3 years) 19.8% 13.3% 18.9%
Hypertension (treated) 71.3% 62.5% 70.1%
Dyslipidemia (treated) 66.8% 63.6% 66.4%
At least 2 cardiovascular risk factors
% of patients 71.2% 62.4% 70.1%
eGFR (MDRD) ‡60 mL/min 86.5% 87.2% 86.6%
DTSQ Diabetes Treatment Satisfaction Questionnaire, eGFR estimated glomerular ﬁltration rate, GP general practitioner, HbA1c glycosylated
hemoglobin, MDRD Modiﬁcation of Diet in Renal Disease, OAD oral antidiabetic drug, SD standard deviation, SPE specialists in endocrinology,
diabetology and metabolic diseases, T2DM type 2 diabetes mellitus
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Compliance with contraindications or
precautions for use of vildagliptin was rather
satisfactory with hepatic impairment reported
in 2.1% of patients and heart failure class III and
IV in 0.3 and 0.0% of patients, respectively.
Liver function tests were available for 80.3% of
patients, among whom 0.6% had aspartate
transaminase (AST) and/or alanine
transaminase (ALT) levels [3 times the upper
limit of normal. Creatinine results were
available in 91% of patients and 11% had
creatinine clearance (CrCl) below the
recommended thresholds in 2009 (50 mL/
min for vildagliptin alone and 60 mL/min for
the metformin-fixed combination). No patient
had end-stage renal disease (\15 mL/min).
The conditions of use of vildagliptin have
been amended since, and it can be used (at a
dose of 50 mg/day) across all degrees of renal
alteration, including in end-stage renal
disease.
Treatment Satisfaction and Maintenance
at 2 Years
After vildagliptin initiation, improvement in
patient treatment satisfaction was important
with an overall DTSQc score of ?9.0 (±5.3),
median 10 (on a scale of -18 to ?18).
The proportion of patients treated with
vildagliptin remained fairly stable over the
course of the study with 92.5% (95% CI
91.2–93.8%) of patients still being treated after
1 year and 88.8% (95% CI 87.2–90.4%) of
patients still treated at 2 years. The rate of
discontinuation over time is presented in
Fig. 2.
The most common reasons for treatment
discontinuation were insufficient efficacy
(39.7% of the reasons) and problems of
tolerability (39.1% of the reasons) both
occurring in about 4% of patients.
Changes in HbA1c and Weight During
Treatment with Vildagliptin
The mean HbA1c decreased sharply in the first
months after vildagliptin initiation from a
mean baseline of 7.8% (±1.2) to 7.0% (±1.0)
at the first follow-up visit held approximately at
6 months, and remained stable thereafter,
throughout the entire follow-up period
(Fig. 3). Due to the complexity of the patients’
treatments schemes over a 2-year period of
follow-up, it is not possible to present all
results according to the detailed treatments
received by the patients. However, results were
consistent for patients included by GP and by
SPE, whether considering vildagliptin alone or
the metformin-fixed combination. Importantly,
similar results were also seen in the main
subpopulation exclusively treated by a dual
metformin/vildagliptin therapy (2/3 of the
population) and also in the large subgroup of
patients who remained treated with dual
therapy only, without any additional
treatment (n = 881, 75%) throughout their
entire follow-up (data not shown). Finally,
further analysis in the sub-population lost to
follow-up before study completion (where
HbA1c values were only available up to
18 months) also showed consistent results.
The percentage of patients with an HbA1c
\7.0% increased from 22.1% initially to 54.0%
at the first visit after vildagliptin initiation, and
that proportion remained stable over the course
of the study with 57.7% of patients having an
HbA1c \7.0% at the last visit after 2 years of
vildagliptin treatment.
Body weight showed a slight insignificant
downward trend of 2.6% over the course of the
study, from 86.0 (±17.7) kg at baseline to 83.8
(±16.6) kg at 24 months. The proportion of
patients whose weight increased by 5% or more
was 8.5% at 24 months.
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Hypoglycemia
Of the 1,639 patients who had at least one
follow-up visit, 8 cases of severe hypoglycemia
were reported in 8 patients (i.e., 0.5% of
patients) and 64 episodes of non-severe
symptomatic hypoglycemia were reported in
47 patients (i.e., 2.9% of patients), namely a
total of 51 patients (3.1%) with 72 episodes of
hypoglycemia during the course of treatment.
All eight cases of severe hypoglycemia occurred
in patients treated concomitantly with insulin
and/or sulphonylureas. Among the 64 episodes
of non-severe symptomatic hypoglycemia, 38
(59%) were also related to a concomitant
treatment with insulin secretagogues
(sulphonylureas and/or meglitinides) and/or
with insulin. Overall, taking into account the
1,639 patients who had at least one follow-up
visit and who were followed-up on average for
1.73 years on treatment with vildagliptin, the
incidence of severe hypoglycemia was 0.24 per
Fig. 3 Changes in HbA1c level over the period of treatment with vildagliptin (solid curve average level, dotted line 95%
conﬁdence interval). HbA1c glycosylated hemoglobin
Fig. 2 Vildagliptin maintenance curve over 2 years (solid curve average level, dotted line 95% conﬁdence interval)
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100 patient years (95% CI 0.10–0.46%) and that
of all hypoglycemic episodes was 2.5 per 100
patient years (95% CI 1.9–3.1%).
In total, 44.9% of patients treated with
vildagliptin had an HbA1c level \7.0%,
without hypoglycemia and without weight
gain ([5% of baseline weight) 6 months after
initiation of vildagliptin. This proportion of
patients meeting ‘‘therapeutic success’’
increased gradually to 49.7% at 24 months
after initiation of vildagliptin.
Safety
The average eGFR, transaminases levels and
lipid parameters remained essentially stable all
along the study. Mean eGFR was 81.9 (±22.0)
mL/min at baseline and 83.1 (±22.5 mL/min) at
the final visit; mean AST/ALT at baseline was
29.5 (±17.6)/28.5 (±15.9) and slightly
decreased to a mean of 27.9 (±12.2)/27.5
(±12.7) at 2 years. Mean low density
lipoproteins (LDL)-cholesterol was 1.1 and
1.0 g/L, respectively (with the % of patients
having C1.3 g/L decreasing from 29.6% at
baseline to 19.4% at the final visit) and high
density lipoproteins (HDL)-cholesterol was
stable at 0.5 g/L both at baseline and final visit
[with a % of men having C0.4 g/L (72.9% then
78.7%) and of women C0.5 g/L (54.1% then
51.7%)].
Safety data were collected on all the 1,763
patients included in the study. Table 2
summarizes the frequency of all AEs, SAEs and
events suspected to be related to the vildagliptin
treatment. Overall, nearly 20% of patients
reported at least one AE over 2 years. The most
frequent events were functional disorders
affecting the gastrointestinal system. Few
patients (1.6%) had at least one event
considered serious and related to vildagliptin.
No case of pancreatitis was reported. Over the
2-year follow-up period, 15 patients of the 1,763
patients in the safety population (0.9%) died of
various causes evaluated as not related to
vildagliptin by the investigators. They had a
mean age of 77 years (range 61–92 years).
DISCUSSION
The pragmatic VILDA study, commissioned by
the French Health Authorities HAS, was
designed to thoroughly describe the use of
vildagliptin in the management of T2DM
under real-life conditions. It brings further
insights into the effectiveness of vildagliptin
in daily medical practice and complement data
on the efficacy/safety profile of the drug
gathered from RCTs for registration. No major
bias was found that might affect the results of
the study in terms of representativeness of
patients and prescribers.
To assess the representativeness of the VILDA
population, it is of interest to compare the
patients with the national sample (2007
‘‘E´chantillon National Te´moin REpre´sentatif
des personnes Diabe´tiques’’ (ENTRED) survey:
conducted to monitor the health status of adult
diabetic patients from a representative sample
of French diabetic patients pharmacologically
treated [34]), even if the T2DM patients
included in VILDA study were inherently
different in that they were seen at the time of
treatment intensification. VILDA participants
were slightly younger (63 years vs. 66 years in
ENTRED), predominantly male (60% vs. 53%),
and their diabetes was more recent (mean
duration from diagnosis of 7 vs. 9 years). The
proportion of obese persons was close (45% and
41%, respectively in VILDA and ENTRED), as
was that of smokers (19% and 16%,
respectively) and of patients receiving
antihypertensive therapy (70% and 75%).
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Erectile dysfunction was reported for 22.8% of
men in the VILDA study, a fairly comparable
rate to the 25% of ENTRED. Mean HbA1c was
higher as expected (7.8% vs. 7.1% overall in
ENTRED), since VILDA participants were
included at time of treatment intensification
and thus frequently had unsatisfactory glucose
control.
The mean HbA1c level of 7.8% at time of
treatment intensification in VILDA was
remarkably consistent with other real-life
studies conducted in France (HYPOCRAS [35])
or in Germany [36], where the mean level
before addition of a second agent was
identical. While in the large, worldwide EDGE
(Effectiveness of Diabetes control with
vildaGliptin and vildagliptin/mEtformin) study
[31], the overall mean HbA1c recognized as
monotherapy failure before the addition of a
second OAD, was slightly higher (8.2%), it was
again very similar in Europe. The DIATTITUDE
study [37] further looked into the behavior of
French GP vis-a`-vis intensification of oral
antidiabetic agents in T2DM patients,
according to their HbA1c level. 41% of patients
had unsatisfactory glucose control (47%, 39%
and 20%, respectively, in monotherapy, dual
therapy and C triple therapy), with an overall
mean HbA1c of 7.5% (7.2%; 7.8% and 9.0%,
respectively, in monotherapy, dual therapy
and C triple therapy). Of these patients,
however, only 7% had their treatment
intensified after the visit. There were
countless reasons for postponing the
pharmacological intensification, many of
them legitimate such as reinforcing lifestyle
advices first or improvement by comparison
with the last measure of glycemic control, but
the so-called ‘‘therapeutic inertia’’ was also
often in play [37].
The efficacy results observed in real-life in
the VILDA study were thoroughly consistent
with those obtained during the RCTs. HbA1c
decreased from a mean baseline of 7.8% to a
mean of 7.0% at the first follow-up visit at
6 months and this reduction was then
maintained over the 2 years of the VILDA
study. Similar results were observed in the
subgroup treated exclusively with vildagliptin
in dual therapy with metformin and who were
prescribed this treatment combination
throughout the study without any other drug.
In RCTs, patients were recruited worldwide and
were on average slightly younger, tended to be
more obese, and often presented with higher
HbA1c [26, 38], with some exceptions [19]. In
the main registration study in add-on to
metformin, a reduction of -0.9% was seen
from a mean baseline of 8.4% [10], while in
another trial in add-on to metformin starting
from a much lower baseline of 7.3%, mean
HbA1c decreased to 6.8% by weeks 12 with
vildagliptin and remained essentially stable
thereafter with a mean HbA1c of 6.75% at
week 52. This illustrates the well known and
typical trend of greater HbA1c reductions seen
from higher baseline levels [39]. A pooled
analysis of phase 3 studies also showed mean
changes in HbA1c with vildagliptin of -0.9%
from a mean baseline of 8.4% in add-on to
Table 2 Summary of adverse events
Safety population
(N5 1,763)
Number (%) of patients with
At least one AE 345 (19.6%)
At least one AE suspected to be
related to vildagliptin
135 (7.7%)
At least one SAE 124 (7.0%)
At least one SAE suspected to be
related to vildagliptin
29 (1.6%)
AE adverse events, SAE severe adverse events
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metformin [26]. Further analysis in add-on to
metformin showed that efficacy was about the
same regardless of BMI, disease duration or
duration of metformin use, with significant
drops in HbA1c of approximately -0.7% from
a mean baseline of 7.7% [15]. This is actually
similar to the results in VILDA from a similar
baseline, in the overall population and in the
main subgroup treated in dual therapy with
metformin. In addition, the results of the
VILDA study highlight the durability of effects
over 2 years, which was also seen in RCTs [20,
40].
Hypoglycemia is one of the main limitations
for glucose-lowering therapy and also a key
factor underlying clinical inertia [41]. Low
hypoglycemic risk is an essential feature of the
DPP4-I class of drugs and has been largely
documented in clinical trials with vildagliptin
[11], stemming from a strong mechanistic
rationale [42]. In a recent German database
study, DPP4-I use was associated with a fivefold
reduced frequency of patients with
hypoglycemia compared to sulphonylureas
(SU) [43]. In the French HYPOCRAS study [35],
the proportion of T2DM patients (of mean age
71) reporting hypoglycemia over 6 months was
6.4% with a DPP4-I vs. 26% with SU or glinides,
and that of severe hypoglycemic events was,
respectively, 0.1% vs. 3.2% (p\0.001). In
keeping with these data, the improvement in
glycemic control in the VILDA study was not
associated with an increased risk of
hypoglycemia, the incidence of which
remained very low over 2 years. Moreover,
severe hypoglycemic episodes were observed
exclusively in combination with insulin-
secreting treatment (SU and/or glinides) and/
or with insulin, and symptomatic episodes
were reported primarily in patients
concomitantly treated with SU and/or glinide
and/or insulin.
Among patients previously treated with SU
and/or glinides before starting vildagliptin, the
proportion of those reporting a history of severe
hypoglycemia was 3.7%. This figure is fairly
comparable to that found in the literature: in
the HYPOCRAS study, 3.2% of patients treated
with an SU or glinide experienced an episode of
severe hypoglycemia over the 6-month study
period [35]. In the ENTRED study, 5% of
subjects’ C65 years treated with SU reported at
least one episode of severe hypoglycemia over a
period of 1 year [44]. Severe hypoglycemia has
been associated with a higher risk of
cardiovascular disease, and this association did
not seem to be solely explained by comorbid
severe illness [45]. Research also demonstrated
the impact of hypoglycemia, as well as fear of
hypoglycemia, on quality of life, related
outcomes and healthcare utilization of people
with T2DM [46, 47]. In a recent prospective
observational study carried out as an addendum
to a mandatory study of the Italian Medicine
Agency (AIFA), the fixed combination
vildagliptin/metformin over 1 year was shown
to improve patient satisfaction, quality of life
(DTSQ) and work productivity measured as
Work Productivity and Activity Impairment
(WPAI) scores [48].
An important dimension that needs to be
taken into account is the adherence to
prescribed medications. Discontinuation of
antidiabetic therapy results in substantial costs
for the healthcare system and appears to be
frequently found in primary care patients. The
ENTRED survey examined medication
adherence using a 6-item self-administered
questionnaire in 3,637 persons with T2DM:
61% of patients reported medium to poor
adherence [49]. This level of medication
adherence was unexpectedly low in France, a
country with a high level of access to
healthcare. In a database study conducted in
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1,201 general practices in Germany [43],
therapy persistence with DPP4-I (19,184 users)
and SU (31,110 users) was compared. Two years
after index date, DDP4-I was associated with a
lower risk of discontinuation compared to SU
(39% vs. 49%) [adjusted hazard ratio (HR) 0.74;
95% CI 0.71–0.76] [43]. In view of these data,
the treatment maintenance rate in the VILDA
study at 2 years was very satisfactory at 88.8%
(95% CI 87.2–90.4%) in line with the improved
satisfaction reported with treatment (?9 at the
DTSQc), and the good and well-maintained
efficacy with few tolerability issues (4% of
patients discontinued treatment for adverse
events over the entire study period) and low
hypoglycemia risk.
This study is also consistent with other real-
life studies worldwide. The largest-scale study
was EDGE, a 1-year, prospective study of more
than 45,000 patients with T2DM not reaching
glycemic targets with monotherapy, conducted
in 27 countries from Europe, Central and Latin
America, Asia and Middle East [31]. Physicians
could add vildagliptin (vildagliptin cohort) or
any other OAD (pooled comparator cohort).
The primary end-point (proportions of patients
with HbA1c decrease [0.3%, without
hypoglycemia, weight gain, peripheral edema
or gastrointestinal side-effects) was attained
more frequently in the vildagliptin vs. the
comparator cohort, with an adjusted odds
ratio of 1.49 (95% CI 1.42, 1.55; p\0.001). In
this setting, vildagliptin as second OAD lowered
HbA1c by about 1% from a mean baseline of
8.2%. Other DPP4-I have been studied as well in
real-life conditions, such as sitagliptin in the
SUGAR study [50], a large Belgian prospective
observational study of shorter duration.
This study has usual strengths and
limitations. Physician participation was
decided on a voluntary basis, which
constitutes a classic potential selection bias in
this type of study. However, the investigators
were representative of all French GP and SPE
across several characteristics, with the exception
of a slightly higher proportion of men among
the VILDA investigators. Another potential
selection bias comes from the fact that the
treating physician chooses which patient was
included into the study. However, comparison
of the patients included with patients from the
non-inclusion registry did not reveal any bias
that might affect the results of this study. Thus,
these data can be considered as reliable and
nicely representative of current care delivery to
diabetic patients treated with vildagliptin in
France. Some patients were lost during the
follow-up. However, the rate of 80.6% of
patients followed over 2 years is satisfactory, in
line with the authors’ statistical hypothesis, and
compares well with other studies of identical
design, such as AVANCE where this rate was
62.4% [51]. Finally, the quality of data
collection in observational studies is always
questioning. The quality of the data collection
was assessed during the survey auditing
collected files in a 5% random sample of
all enrolled patients. Audit results were
positive not showing serious irregularities or
anomalies.
CONCLUSION
The present study provides important
information for management of T2DM in
daily practice, as it emphasizes the
effectiveness of vildagliptin treatment, with a
low risk of hypoglycemia and fairly good
persistence at mid-term, in a large
population of patients in the real-world
environment. It confirms the results obtained
under controlled conditions in selected
patients from RCTs.
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